Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14679935 | 1.00 | RAB9A (0.46) | RAB9AKDM4ENPC1SMN1; SMN2ABCB1 | |
| SCHEMBL20954693 | 1.00 | RAB9A (0.46) | RAB9AKDM4ENPC1SMN1; SMN2ABCB1 | |
| SCHEMBL3710880 | 1.00 | RAB9A (0.46) | RAB9AKDM4ENPC1SMN1; SMN2ABCB1 | |
| SCHEMBL9548553 | 1.00 | RAB9A (0.46) | RAB9AKDM4ENPC1SMN1; SMN2ABCB1 | |
| SCHEMBL15445614 | 1.00 | RAB9A (0.46) | RAB9AKDM4ENPC1SMN1; SMN2ABCB1 | |
| SCHEMBL9235818 | 1.00 | RAB9A (0.46) | RAB9AKDM4ENPC1SMN1; SMN2ABCB1 | |
| SCHEMBL8105735 | 0.88 | RAB9A (0.35) | RAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL13851802 | 0.83 | CYP1A2 (0.35) | RAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL13851731 | 0.83 | CYP1A2 (0.35) | RAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL3662933 | 0.83 | CYP1A2 (0.35) | RAB9AKDM4ENPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-11343280-A | — | — | None | — | — | JP | disclosed |
| EP-0978284-B1 | USE OF 15-KETO-PROSTAGLANDIN-E COMPOUNDS AS ENDOTHELIN ANTAGONISTS | SUCAMPO AG (CH) | 2008-07-23 | — | — | EP | disclosed |
| EP-1097922-B1 | 5-THIA-OMEGA-SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2005-03-16 | — | — | EP | disclosed |
| US-6462081-B1 | SUCH AS A 9-OXO-11,15-DIHYDROXY-16-(3-METHOXYMETHYLPHENYL)-17,18,19,20-TETRANOR-5 -THIAPROST-13-ENOIC ACID; PROSTAGLANDIN E2 RECEPTOR BINDERS; AMYOTROPHIC LATERAL SCLEROSIS, LUPUS, MULTIPLE SCLEROSIS, SJOEGREN'S SYNDROME, RHEUMARTHROSIS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-10-08 | — | — | US | disclosed |
| EP-1097922-A1 | 5-THIA-OMEGA-SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-05-09 | — | — | EP | disclosed |
| US-6197821-B1 | NEW USE OF 15-KETO-PROSTAGLANDIN E COMPOUNDS, HYPERTENSION, BUERGER DISEASE, RAYNAUD DISEASE, ASTHMA, EYEGROUNDS--AMPHIBLESTRODES, CHORIOIDEA, DIABETES, ARTERIAL SCLEROSIS, RENAL FAILURE, CARDIAC INFARCTION, ANGINA PECTORIS | R-TECH UENO, LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-0978284-A1 | ENDOTHELIN ANTAGONIST | R-Tech Ueno, Ltd. (JP) | 2000-02-09 | — | — | EP | disclosed |
| JP-H11343280-A | PROSTAGLANDIN COMPOUND | R TEC UENO:KK | 1999-12-14 | — | — | JP | disclosed |
| EP-0690049-B1 | Agent for treating hepato biliary diseases | R TECH UENO LTD (JP) | 1999-08-04 | — | — | EP | disclosed |
| EP-0455448-B1 | Treatment of pancreatic disease with 15-keto-prostaglandin E compounds | R TECH UENO LTD (JP) | 1998-12-09 | — | — | EP | disclosed |
| US-5164415-A | Amylase inhibitor | K.K. UENO SEIYAKU OYO KENKYUJO (JP) | 1992-11-17 | — | — | US | disclosed |
| EP-0503887-A2 | Promotion of wound-healing with 15-keto-prostaglandin compounds | R-TECH UENO LTD. (JP) | 1992-09-16 | — | — | EP | disclosed |
| US-5117042-A | 15-KETO-PROSTAGLANDIN COMPOUND FOR IMPROVEMENT OF ENCEPHALIC FUNCTION | K.K. UENO SEIYAKU OYO KENKYUJO (JP) | 1992-05-26 | — | — | US | disclosed |
| US-5096927-A | Treatment for liver disorders | K.K. UENO SEIYAKU OYO KENKYUJO (JP) | 1992-03-17 | — | — | US | disclosed |
| EP-0467564-A2 | Treatment of inflammatory diseases with 15-keto-prostaglandin compounds | R-TECH UENO LTD. (JP) | 1992-01-22 | — | — | EP | disclosed |
| EP-0455448-A2 | Treatment of pancreatic disease with 15-keto-prostaglandin compounds | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo (JP) | 1991-11-06 | — | — | EP | disclosed |
| EP-0453127-A2 | Treatment of cataract with 15-keto-prostaglandin compounds | R-TECH UENO LTD. (JP) | 1991-10-23 | — | — | EP | disclosed |
| EP-0435443-A2 | Use of 15-keto-prostaglandin compound for improvement of encephalic function | R-TECH UENO LTD. (JP) | 1991-07-03 | — | — | EP | disclosed |
| EP-0430552-A2 | Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo (JP) | 1991-06-05 | — | — | EP | disclosed |
| EP-0424156-A2 | Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds | R-TECH UENO LTD. (JP) | 1991-04-24 | — | — | EP | disclosed |